A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours by Baruchel, Sylvain et al.
E U R O P E A N J O U R N A L O F C A N C E R 4 5 ( 2 0 0 9 ) 2 3 5 2 –2 3 5 9
. sc iencedi rec t .comava i lab le at wwwjournal homepage: www.ejconl ine.comA Canadian paediatric brain tumour consortium (CPBTC)
phase II molecularly targeted study of imatinib in recurrent
and refractory paediatric central nervous system tumoursSylvain Baruchela,*, Julia R. Sharpa, Ute Bartelsa, Juliette Hukinb, Isaac Odamec,
Carol Portwinec, Doug Strotherd, Chris Fryerb, Jackie Haltone, Merrill J. Egorinf,
Rui Manuel Reisg, Olga Martinhog, Diana Stempaka, Cynthia Hawkinsh,
Janet Gammona, Eric Bouffeta
aNew Agent and Innovative Therapy Program, Department of Paediatrics Division of Haematology/Oncology,
Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8
bDepartment of Haematology/Oncology, British Columbia Children’s Hospital, 4480 Oak Street, Vancouver, British Columbia,
Canada V6H 3V4
cDepartment of Paediatrics, Division of Haematology/Oncology, McMaster University Medical Center,
1200 Main Street West Hamilton, Ontario, Canada L8N 3Z5
dDepartment of Haematology/Oncology, Alberta Children’s Hospital, 2888 Shaganappi Trail North West, Calgary, Alberta, Canada T3B 6A8
eDepartment of Haematology/Oncology, Children’s Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario, Canada K1H 8L1
fDepartment of Medicine and Pharmacology, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, 15232 Pittsburgh, PA, USA
gLife and Health Science Research Institute (ICVS), School of Health Sciences, University of Minho,
Campus de Gualtar, 4710-057 Braga, Portugal
hDepartment of Paediatric Laboratory Medicine, Division of Pathology, The Hospital for Sick Children, 555 University Avenue,
Toronto, Ontario, Canada M5G 1X8A R T I C L E I N F O
Article history:
Received 13 February 2009
Received in revised form 16 April
2009
Accepted 7 May 2009





Central nervous system neoplasms
Brain neoplasms




Pharmacokinetics0959-8049/$ - see front matter  2009 Elsevi
doi:10.1016/j.ejca.2009.05.008
* Corresponding author: Tel.: +1 416 813 7795
E-mail address: sylvain.baruchel@sickkidA B S T R A C T
Purpose: To evaluate the safety, efficacy and pharmacokinetics of imatinib in children with
recurrent or refractory central nervous system (CNS) tumours expressing KIT and/or PDG-
FRA.
Methods: Nineteen patients aged 2–18 years, with recurrent or refractory CNS tumours
expressing either of the target receptors KIT and/or PDGFRA (by immunohistochemistry)
were eligible. Participants received imatinib orally at a dose of 440 mg/m2/day and toxicities
and tumour responses were monitored. Serial blood and cerebrospinal fluid samples for
pharmacokinetics were obtained in a subset of consenting patients. Frozen tumour sam-
ples were analysed retrospectively for KIT and PDGFRA gene amplification in a subset of
patients for whom samples were available.
Results: Common toxicities were lymphopaenia, neutropaenia, leucopaenia, elevated
serum transaminases and vomiting. No intratumoural haemorrhages were observed.
Although there were no objective responses to imatinib, four patients had long-term stable
disease (SD) (38–104 weeks). Our results suggest a possible relationship between KIT
expression and maintenance of SD with imatinib treatment; KIT immunopositivity was
seen in only 58% (11/19) of study participants overall, but in 100% of patients with SD ater Ltd. All rights reserved.
; fax: +1 416 813 5327.
s.ca (S. Baruchel).
E U R O P E A N J O U R N A L O F C A N C E R 4 5 ( 2 0 0 9 ) 2 3 5 2 –2 3 5 9 235338 weeks. All patient tumours showed PDGFRA expression. Pharmacokinetic data showed a
high interpatient variability, but corresponded with previously reported values.
Conclusions: Imatinib at 440 mg/m2/day is relatively safe in children with recurrent CNS
tumours, but induced no objective responses. Demonstration of SD in previously progress-
ing patients (KIT-expressing) suggests cytostatic activity of imatinib.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Central nervous system (CNS) tumours are the second most
frequent malignancy and most common form of solid tumour
in children. With a 5-year survival rate of 65%, these tumours
are the leading cause of cancer-related mortality in children,
despite aggressive multi-modal therapy.1 In addition, effects
of either treatment or the tumour itself often leave survivors
of childhood CNS tumours with significant neurologic, neuro-
cognitive and psychosocial sequelae.1,2 Better treatment ap-
proaches are needed.
Imatinib mesylate (STI571) is a targeted small molecule
competitive inhibitor of subclass III receptor tyrosine ki-
nases, including KIT and PDGFRA.3,4 KIT is a proto-oncogene
that encodes KIT (CD117),5 which, when bound to its ligand
stem cell factor, is implicated in signalling leading to cell
proliferation.6 The role of KIT in tumourigenesis has been
best studied in gastrointestinal stromal tumours (GISTs)
where KIT is commonly mutated, causing constitutive, li-
gand-independent activations of KIT responsible for onco-
genic potential.7,8
The two PDGF receptors, a and b, can be found on fibro-
blasts, glial cells and vascular smooth muscle cells, where
PDGF binding results in cell proliferation, differentiation and
migration.9 In addition, studies show that imatinib reduces
the expression of VEGF, a downstream effector in the PDGF
pathway,10 suggesting that imatinib may have indirect anti-
angiogenic activity via its inhibition of PDGFRA. Mutations
in both the PDGFRA and KIT genes correlate with GIST tumour
response to treatment.4
Imatinib treatment has shown significant clinical re-
sponses in KIT-expressing GIST11,12 in adults, and in chronic
myeloid leukaemia (CML) expressing the BCR-ABL fusion pro-
tein in both adults13 and children.14,15 Overexpression of KIT
and PDGFRA has been demonstrated in multiple paediatric
brain tumours; medulloblastoma,16 neuroblastoma,17 intra-
cranial germinoma,18 and more recently astrocytoma,19
showed KIToverexpression, while PDGFRAwas overexpressed
in paediatric astrocytoma and in a small percentage of paedi-
atric gliomas.19,20
Evidence of successful clinical studies in malignancies
expressing imatinib targets, and of target expression in vari-
ous paediatric brain tumours, provided the rationale to con-
duct a phase II study evaluating efficacy and safety of
imatinib in paediatric patients with recurrent or refractory
CNS tumours. Objectives of the study were: to assess clinical
efficacy, safety and pharmacokinetics of imatinib; to assess
the frequency of KIT and PDGFRA expression and to correlate
efficacy with expression.2. Patients and methods
2.1. Patients
This was a multi-centre Canadian study. Patients 621 years of
age with histologically confirmed recurrent or refractory CNS
tumours expressing KIT and/or PDGFRA by immunohisto-
chemistry were eligible for study. Patients were stratified into
those with (stratum 1) or without (stratum 2) leptomeningeal
dissemination of disease. At baseline, patients were required
to have measurable disease documented by CTor MRI. Lepto-
meningeal dissemination was defined as positive findings on
spine MRI, or as presence of malignant cytology or abnor-
mally high protein in cerebrospinal fluid (CSF).
Additional eligibility criteria included Lansky performance
score P40% or Karnofsky score P50%, life expectancy P8
weeks, adequate bonemarrow function (ANCP1500/lL, plate-
let countP100,000/lL haemoglobinP8.0 g/dL), adequate liver
function (total bilirubin 61.5 · upper limit of normal for age,
ALT62.5 · upper limit of normal for age), adequate renal func-
tion (age-adjusted normal serum creatinine or GFR P70 ml/
min/1.73 m2) andnormal coagulation (INR61.5, PTTandfibrin-
ogen normal). Negative pregnancy tests were required in post-
menarchal females. All patients of reproductive age agreed to
effective contraceptive use. Pregnant or breast-feedingwomen
were excluded. Patients requiring drugs known to activate the
cytochrome p450 enzyme system (including enzyme-inducing
anti-epileptic drugs) and patientswithmedical conditions that
could alter imatinib metabolism were excluded.
The study was approved by the institutional review board
of each participating institution and conducted in accordance
with the institutional and federal guidelines for human inves-
tigations. Patients and parents signed institutional review
board–approved informed consent forms before enrolment.
2.2. Criteria for response and progression
Tumour response was determined using National Cancer
Institute Response Evaluation Criteria in Solid Tumours (RE-
CIST). Progressive disease (PD) was defined as P20% increase
in cross-sectional area of a lesion or the appearance of new
lesions or malignant cells in previously normal CSF. Complete
response (CR) was defined as the complete disappearance of
target lesions, partial response (PR) as at least 30% decrease
in disease measurement, and stable disease (SD) as neither
sufficient shrinkage to qualify for PR nor sufficient increase
to qualify for PD. Lesions were measured using either CT or
MRI (single modality for each patient) at baseline, following
course 1, and following every alternate course thereafter.
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Immunostaining was centrally performed. About 5 lm for-
malin-fixed, paraffin-embedded tissue sections were
mounted on positively charged microscope slides and baked
overnight at 60 C prior to immunostaining. Immunohisto-
chemistry was performed on the Ventana BenchmarkTM
auto-immuno stainer using the UltraView multimer DAB
detection system for the polyclonal rabbit anti-human KIT
(CD117) (Dako, Carpinteria, CA, United States of America),
and iVIEW DAB, LSAB detection system for the Polyclonal
Rabbit anti-human PDGFRA (Santa Cruz Biotechnology, San-
ta Cruz, CA, USA) at dilutions of 1:50 and 1:100, respectively.
Staining was scored on an arbitrary scale based on strength:
0 = no staining; 1 = weak staining and 2 = strong staining.
Control tissue cells (duodenal mast cells and angiofibroma
cells for KIT and PDGFRA, respectively) were used as an
internal scoring guide (score 2).
2.4. Treatment administration
Patients had to begin treatment within 14 days of obtaining
radiological proof of recurrent or refractory disease. Imatinib
was provided by Novartis Pharmaceuticals in 100 mg cap-
sules. Patients in both strata took imatinib orally at a dose
of 440 mg/m2/day (rounded to nearest multiple of 100 mg)
for courses of 28 days with no interruptions. Imatinib was di-
vided BID for doses P600 mg/day, and given to a maximum
dose of 800 mg/day. No dose escalation was allowed. Patients
with PD or unacceptable toxicity were taken off study. In the
absence of PD, drug-related toxicities were managed by dose
interruption or reduction based on the protocol guidelines.
Patients who demonstrated SD, PR or CR were eligible to re-
ceive therapy for up to 2 years. No other cancer chemotherapy
or immunomodulating agents were used.
2.5. Definition of toxicity
Toxicities were graded using National Cancer Institute Com-
mon Toxicity Criteria (NCI-CTC) Version 2.0. Safety assess-
ments included regular monitoring of haematological
parameters, blood chemistry analysis, urinalysis, vital signs,
physical condition andweight. For adverse events and serious
adverse events, severity, duration, outcome and presumed
relationship to study drug were recorded.
2.6. Pharmacokinetic evaluation
On day one of treatment, 2 ml of heparinised blood samples
were obtained before morning drug administration and at
hours 0.5, 1, 2, 3, 4, 8, 11:55 (before second dose if BID dosing),
24 and 48 following drug administration. A trough level on
day 8 was obtained prior to drug ingestion. Plasma was pre-
pared by centrifugation and stored at –80 C until it was ana-
lysed for drug content. Sampling of CSF was done at baseline
in cases of leptomeningeal dissemination, and repeated 4 h
after morning drug administration on day 15, 28 (end of cycle
1) and 56 (end of cycle 2).
Plasma and CSF concentrations of imatinib and its active
metabolite N-desmethyl-imatinib (CGP74588) were deter-mined using a validated liquid chromatography/mass spec-
trometry assay as previously reported.21
2.7. QRT-PCR evaluation for KIT and PDGFRA
For quantitative real-time PCR (QRT-PCR), 10 lm sections of
paraffin blocks were cut and selected areas containing at least
85% of tumour were marked for DNA isolation as previously
described.22 QRT-PCR was performed with LightCycler (Roche
Molecular Biochemicals, Mannheim, Germany). Primers and
probes were designed to amplify a 124 bp (exon 18 from PDG-
FRA gene), 163 bp (exon 17 from KIT gene) and 147 bp (18S
gene) specific PCR product, where 18S was used as reference
gene. PCR amplification conditions, primers and probes for
18S and KITwere previously described.22 For PDGFRA, condi-
tions were as follows: 5 0-TCAGCTACAGATGGCTTGATCC-3 0
(forward primer), 5 0-GCCAAAGTCACAGATCTTCACAAT-3 0 (re-
verse primer), 5 0-TGTGTCCACCGTGATCTGGCTGC-FL (donator
probe), LC640-CGCAACGTCCTCCTGGCACAAGG-3 0 (acceptor
probe).
Evaluation of data was performed using the DDCt method:
DDCt = DCt Tumour DNA – DCt Normal blood DNA. DCt
(threshold cycles) is the Ct of the reference gene minus the
Ct of the target gene. Fold increase of the target gene was cal-
culated by 2(DDCt).Values between 2 and 5 were considered as
aneuploidy and values P5 were considered as gene
amplification.
2.8. Statistical analysis
The study was designed as an intent-to-treat study. The pri-
mary end-point was objective response rate as assessed by
RECIST criteria. Secondary end-point criteria included toxici-
ties as assessed by the NCI-CTC, and pharmacokinetic data,




Between August 25, 2003 and March 26, 2007, 19 patients were
enroled for the study at 5 study centres: 9 patients without,
and 10 patients with, CNS dissemination (strata 1 and 2,
respectively). Median age at study entry was 10 (range 3–18)
for stratum 1 and 8.5 (range 2–17) for stratum 2. Characteris-
tics of patients are presented in Table 1.
One patient was excluded from analysis of toxicity due to
very early progression. Seven patients consented to blood
draws for pharmacokinetics but only fivewere fully evaluable.
No patients had 48-hour samples taken on day 1 due to issues
of consent. One patient consented to CSF samples for phar-
macokinetics analysis. Archival frozen tumour samples for
retrospective QRT-PCR analysis of gene amplification were
available for three patients.
3.2. Safety and toxicity
Safety was assessed in 18 patients who completedP1 course
of imatinib. At the time of study closure, 70 total courses of
Table 1 – Characteristics of eligible patients at baseline.
Stratum 1 (n = 9)
(No CNS dissemination)




Age at enrolment (years)
Median (range) 10 (3–18) 8.5 (2–17) 9 (2–18)
Gender
Female 3 4 7
Male 6 6 12
Histology
Astrocytoma 2 1 3
Ependymoma 3 2 5
GBM 1 1 2
Medulloblastoma/PNET 2 6 8
Neurocytoma 1 0 1
Receptor staining
PDGFRA+ (%) 9 (100%) 10 (100%) 19 (100%)
KIT+ (%) 7 (77.8%) 4 (40%) 11 (57.9%)
Performance statusa
Median (range) 70 (60–100) 90 (50–100) 80 (50–100)
Weeks since diagnosis
Median (range) 9 (4–43) 13 (2–39) 12 (2–43)
Disease status prior to study entry
SD 2 1 3
PD 7 9 16
Relapse numberb
Median (range) 2 (1–3) 2 (1–5) 2 (1–5)
Prior chemotherapy regimens
Median (range) 1 (1–4) 2 (0–3) 2 (0–4)
0 0 1 1
1 6 2 8
2 2 4 6
3 0 3 3
4 1 0 1
Prior RT regimens
Median (range) 1 (0–2) 1 (1–1) 1 (0–2)
0 1 0 1
1 7 10 17
2 1 0 1
Prior BMT
Number of patients 0 1 1
GBM, glioblastoma multiforme; PNET, primitive neuroectodermal tumour; SD, stable disease; PD, progressive disease; RT, radiation therapy;
BMT, bone marrow transplant.
a Lansky (patients <10-years-old) or Karnofsky (patientsP10-years-old) score was used. N = 17, as scores were not available for two stratum 1
patients.
b N = 16; two patients in stratum 1 and one patient in stratum 2 had refractory tumours, and thus had no relapses.
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stratum 2. Median number of cycles per patient was one for
stratum 1 (range 1–26), and one for stratum 2 (range 1–4). Most
patients received imatinib daily with no interruptions. How-
ever, two patients had P7 days of treatment interruption
due to toxicities likely related to imatinib: one patient had
grade 3 diarrhoea in courses 2 and 4, with treatment interrup-
tion for 7 and 8 days, respectively; another patient had hypo-
albuminaemia and oedema in cycle 7, with treatment
interruption for 20 consecutive days. Both the patients were
in stratum 1. Dose reductions following adverse events were
made in two stratum 1 patients after course 1. Of all study pa-tients, five (four in stratum 1) received imatinib for
P16 weeks, and four (all stratum 1) received for P38 weeks.
Course 1 adverse events are summarised in Table 2. Hae-
matological toxicities were common during course 1; lympho-
paenia, neutropaenia, thrombocytopaenia and leucopaenia
all occurred in P4 (20%) of patients. The most commonly re-
ported non-haematological toxicities in course 1 were vomit-
ing, nausea, diarrhoea, elevated ALT, skin rash and fatigue.
Three serious adverse events were considered related to
imatinib. One patient was hospitalised during course 1 for
disseminated shingles infection with high-grade thrombocy-
topaenia and ALT/AST elevation; this patient died while on
Table 2 – Grades 1–2 and 3–4 NCI-CTC imatinib-related toxicities reported during course 1 (n = 18).a
Event Grades 1–2 Grades 3–4
No. pts (%) No. pts (%)
Haematological
Lymphopaenia 7 38.9 1 5.6
Neutropaenia 4 22.2 2b 11.1
Thrombocytopaenia 4 22.2 0 0
Leukocytes 6 33.3 1 5.6
Non-haematological
ALT 5 27.8 1 5.6
Diarrhoea 3 16.7 0 0
Vomiting 6 33.3 1 5.6
Pulmonary (wheeze) 0 1 5.6
Infection 1 5.6 1 5.6
Fatigue 2 11.1 1 5.6
Creatinine 1 16.7 0 0
Constipation 1 5.6 0 0
Dehydration 1 5.6 0 0
Weight loss 1 5.6 0 0
Nausea 4 22.2 0 0
Headache 2 11.1 0 0
Blurred vision 1 5.6 0 0
Skin rash 3 16.7 0 0
Cramping/spasm 1 5.6 0 0
Swelling 1 5.6 0 0
Dizziness 1 5.6 0 0
Ataxia 1 5.6 0 0
Poor appetite 1 5.6 0 0
Haematuria 1 5.6 0 0
a Note that one patient was excluded from evaluation of toxicity, because this patient did not complete a full course of imatinib.
b Imatinib had to be held for 8 days for one of these patients.
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buminaemia and oedema, vomiting, diarrhoea and constipa-
tion post-course 7. After recovery, treatment was resumed at
75% dose. Another patient was hospitalised during course 9
for pneumonia, thrombocytopaenia, diarrhoea, ascites and
haemorrhagic pleural and pericardial effusions, and was ta-
ken off study due to unacceptable toxicity. Five patients died
within 28 days of the last dose of imatinib. None were related
to the study drug.
3.3. Outcome results
Tumour response was assessed in all 19 patients. There were
no PRs or CRs to treatment. Four patients maintained SD
P38 weeks on treatment (all stratum 1), including one patient
each with ependymoma, astrocytoma, medulloblastoma and
primitive neuroectodermal tumour (PNET). All others had
progressed by 16 weeks. The PNET patient had SD with a
refractory tumour upon study entry, maintained SD for
104 weeks (26 courses), and was taken off study after comple-
tion of 2 years. This patient progressed 6 months later. Of the
patients who maintained SD, three of four were progressing
prior to study entry. The PNET patient entered the study with
refractory SD, maintained SD for 104 weeks (26 courses) with
imatinib treatment, and was taken off study after completion
of 2 years. This patient progressed 6 months later. The astro-
cytoma, medulloblastoma, and ependymoma patients all had
PD upon study entry and maintained SD for 38, 38, and 39
weeks, respectively, with imatinib treatment. The medullo-blastoma patient still had SD when taken off study for unac-
ceptable toxicity (pericardial and pleural effusion) at
38 weeks. The others were taken off study for PD.
3.4. Pharmacokinetic analyses
Pharmacokinetic data were available for five patients. Based
on body surface area, one patient received 500 mg/day, three
received 600 mg/day (300 mg BID), and one received 700 mg/
day (300 and 400 mg). Patients receiving doses of BID under-
went PK analysis based on the 300 mg morning dose. CSF
samples were available for one patient at the 300 mg BID dose
level. Considerable interpatient variability of imatinib phar-
macokinetics was observed. Details are reported in Table 3.
The CSF samples were obtained at pre-treatment, day 15
and day 28. At day 28 the sample was contaminated with
blood and was not useable. At day 15, imatinib concentration
was 92 ng/ml and CGP74588 concentration was 13 ng/ml. This
was less than 5% of corresponding plasma levels, suggesting a
weak penetration of imatinib into the CNS.
3.5. Immunostaining results
While assessing study eligibility, 35 total patient tumour sam-
ples were tested for KIT and PDGFRA immunostaining. All 35
patients were immunopositive for PDGFRA, while only 17
(49%) were immunopositive for KIT. No single tumour type
showed a reliable pattern of KIT expression. Only 5 of 8
(63%) medulloblastoma/PNET patients tested positive for
Table 3 – Pharmacokinetic data based on serum concentration after morning dose.a
Dose level
300 mg 500 mg
Median (ng/ml) Range (ng/ml)
Day 1 (n = 4) (n = 1)
Imatinib Cmax 2549 1728–2968 4867
Imatinib trough 277 123–350 862
CGP74588 Cmax 345 170–407 1060
CGP74588 trough 123 65–350 322
Day 8 (n = 3) (n = 1)
Imatinib concentration 3297 2103–3725 2067
CGP74588 concentration 570 469–897 819
a Patients at 300 mg dose for pharmacokinetics were those with doses of 600 or 700 mg/day divided BID. Their trough level was taken at 11:55 h,
prior to their second dose. The patient at 500 mg dose level had a daily imatinib dose of 500 mg/day taken at once. This patient’s trough level was
taken at 23:55 h, prior to dosing for the next day.
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of 10 medulloblastoma samples expressed KIT.16
Of the 19 study patients, 11 (58%) were positive for KIT. Of
note, however, is that of the 4 patients with SD at 38 weeks, all
4 (100%) were KIT positive.
3.6. QRT-PCR evaluation for KIT and PDGFRA
Archival pre-treatment tumour pathology specimens were
available for three of 19 study patients. The samples were
evaluated retrospectively for amplification of KIT and PDGFRA
genes to assess for correlation with response to imatinib.
None of the tumours samples exhibited gene amplification
of either KIT or PDGFRA, thus we were unable to assess rela-
tion to outcome.
4. Discussion
Imatinib at a dose of 440 mg/m2/day was evaluated in the
treatment of recurrent or refractory paediatric CNS tumours
expressing KIT or PDGRFA. Given the efficacy of imatinib
treatment in cancers expressing these targets and confirma-
tion of expression in patients’ tumour samples, there was
strong rationale to evaluate imatinib in this setting.
No objective tumour responses (either CR or PR) were ob-
served. Another recent paediatric study of imatinib treatment
for CNS tumours shows similarly disappointing results, with
no CRs observed, and very low PR rates.23 A recent study in
adult recurrent gliomas showed similarly poor clinical
responses.24
In this study, four patients (21%) maintained SD longer
than 38 weeks, yet all but one had progressed by 1 year. This
is congruent with the above-mentioned study in adult recur-
rent gliomas, in which imatinib treatment resulted in SD in
25%, and in PR in only 5% of patients.24 Another recent study
on recurrent adult gliomas showed SD in 20%, and PR in 4% of
patients.25 These data suggest that imatinib may have cyto-
static activity in adult CNS tumours. Given that some patients
with PD just prior to study entry achieved SD with imatinib
treatment, our data suggest some cytostatic activity of imati-
nib in paediatric CNS tumours. Given that all four patientswith SD at 38 weeks had KIT-expressing tumours, KIT may
correlate with maintenance of SD with imatinib treatment.
However, we cannot draw firm conclusions about cytostatic
activity of imatinib or the correlation of KITwith SD, because
the heterogeneity and rarity of these tumours limit the avail-
ability of historical controls for comparison.
There are several potential explanations for lack of objec-
tive response to imatinib treatment. Imatinib penetration of
the blood brain barrier (BBB) is poor. Recent reports have doc-
umented CSF imatinib levels 40- to 92-fold lower than the cor-
responding plasma levels in adults with intact BBBs treated
for CML and acute lymphoblastic leukaemia.26,27 Data from
our study showed that CSF levels of imatinib are less than
5% of the corresponding plasma levels. Access to the CSF is
likely limited by drug efflux pumps such as P-glycoprotein,
which is highly expressed in the BBB.28 Low CSF concentra-
tions of imatinib likely contribute to its limited efficacy in
CNS tumours, despite the possibility for partial BBB disrup-
tion in these patients. Dasatinib, a second-generation recep-
tor tyrosine kinase inhibitor crosses the BBB effectively
despite P-glycoprotein expression, and has shown a signifi-
cant clinical activity in adult CML patients with CNS involve-
ment.29 Future assessment of the efficacy of second-
generation tyrosine kinase inhibitors in CNS tumours should
be considered.
Previous studies assessing imatinib in CNS tumours,
which have based treatment rationale on published findings
that these tumour types frequently overexpress imatinib tar-
gets, have found similarly limited evidence of clinical efficacy
of imatinib as a single agent. To our knowledge, this study is
the first to use target receptor expression status as eligibility
criteria for an imatinib study. Despite the fact that the patient
tumours had confirmed the expression of imatinib targets,
treatment showed limited clinical activity in paediatric CNS
tumours. This suggests that target expression is not sufficient
to predict imatinib activity. However, the mutation status of
both KIT and PDGFRA has been found retrospectively to be
predictive of imatinib response in GIST.4,30 In addition, the
specific mutation genotype of KIT is predictive of the imatinib
dose required for clinical responses in GIST; tumours with
exon 11 mutations responded to low dose imatinib, while
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from treatment with higher doses of imatinib.31 Given these
findings, future studies of imatinib combinations in paediat-
ric CNS tumours should consider mutational analysis, rather
than expression, of KIT and PDGFRA as potential predictors of
tumour response to imatinib.
This study confirmed the phase II dose of 440 mg/m2/day
for imatinib treatment in children.14 Toxicities were accept-
able and all had been previously reported in children.14,23
None of the patients experienced intratumoural haemor-
rhage, a previously reported toxicity associated with imatinib
treatment for solid tumours in children and adults.23,25
Pharmacokinetic analysis showed a considerable interpa-
tient variability, as seen in previously published paediatric
studies using a similar dosing.14,23 Compared with these stud-
ies, our data show similar ranges for serum Cmax on day 1 and
day 8 for both imatinib and its active metabolite CGP74588.
The findings of SD in this study and prior adult studies
suggest cytostatic activity of imatinib in some CNS tu-
mours.24,25 In a recent phase I study of recurrent malignant
gliomas in adults, combination of imatinib with temozolo-
mide was well tolerated and showed promising results, with
12% of patients achieving PR or CR.32 Imatinib in combination
with a cytotoxic agent may have a similar clinical efficacy in
paediatric CNS tumours. Future preclinical and phase I stud-
ies are needed to evaluate the safety and preliminary evi-
dence of efficacy of this treatment.
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